Ezogabine

Generic Name: Ezogabine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₈FN_₃O_₂

CAS Number: 150812-12-7

Unique Ingredient Identifier: 12G01I6BBU

Background: Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy. FDA approved in June 10, 2011 under the name of ezogabine.

Indication: Adjuvant treatment of partial-onset seizures.

Associated Conditions: Refractory Partial Onset Seizures

Associated Therapies: -

Clinical Trials

Study to Treat Major Depressive Disorder With a New Medication

Phase 2

Completed

Conditions: Depressive Disorder
Anhedonia

Interventions: Drug: Placebos
Drug: Ezogabine

First Posted Date: 2017-02-06

Last Posted Date: 2020-10-23

Lead Sponsor: James Murrough

Target Recruit Count: 45

Registration Number: NCT03043560

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States

Clinical Trial of Ezogabine (Retigabine) in ALS Subjects

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Ezogabine
Drug: Placebo

First Posted Date: 2015-05-21

Last Posted Date: 2019-08-28

Lead Sponsor: Brian Wainger

Target Recruit Count: 65

Registration Number: NCT02450552

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
UC Irvine Medical Center, Orange, California, United States

and more 9 locations

Study to Treat Major Depressive Disorder (MDD) With a New Medication

Phase 2

Completed

Conditions: Major Depressive Disorder
Depression

Interventions: Drug: ezogabine

First Posted Date: 2014-05-29

Last Posted Date: 2019-04-16

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 18

Registration Number: NCT02149836

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study

Phase 3

Completed

Conditions: Epilepsy

Interventions: Drug: retigabine
Drug: placebo

First Posted Date: 2013-04-04

Last Posted Date: 2014-12-02

Lead Sponsor: University Hospital of Mont-Godinne

Target Recruit Count: 15

Registration Number: NCT01823159

Locations: 🇧🇪
CHU Mont-Godinne, Yvoir, Namur, Belgium

Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects

Phase 1

Withdrawn

Conditions: Epilepsy, Partial

Interventions: Drug: Retigabine

First Posted Date: 2012-09-25

Last Posted Date: 2018-09-17

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT01691872

Locations: 🇯🇵
GSK Investigational Site, Kagoshima, Japan

Bioavailability of Different n-3 Fatty Acid Formulations

Phase 4

Completed

Conditions: Health

Interventions: Drug: GArTG
Drug: EE
Drug: KPL
Drug: rTG

First Posted Date: 2010-10-05

Last Posted Date: 2011-12-07

Lead Sponsor: Gottfried Wilhelm Leibniz Universität Hannover

Target Recruit Count: 12

Registration Number: NCT01214278

Locations: 🇩🇪
Gottfried Wilhelm leibniz University of Hanover, Hanover, Lower Saxony, Germany

Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)

Phase 2

Completed

Conditions: Postherpetic Neuralgia

Interventions: Drug: Retigabine
Drug: Placebo

First Posted Date: 2008-02-11

Last Posted Date: 2018-05-08

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 187

Registration Number: NCT00612105

Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy

Phase 3

Completed

Conditions: Seizures

Interventions: Drug: Retigabine
Drug: Placebo

First Posted Date: 2005-10-10

Last Posted Date: 2017-04-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 539

Registration Number: NCT00235755

Locations: 🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇺🇸
Neurological Clinic-Texas, Dallas, Texas, United States
🇩🇪
University of Bonn -- Department for Epileptplogy, Bonn, Germany

and more 67 locations

Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy

Phase 3

Completed

Conditions: Seizures

Interventions: Drug: Placebo
Drug: Retigabine

First Posted Date: 2005-10-04

Last Posted Date: 2016-12-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 306

Registration Number: NCT00232596

Locations: 🇺🇸
McFarland Clinic, Ames, Iowa, United States
🇺🇸
Oregon Neurology PC, Tualatin, Oregon, United States
🇦🇷
Fundacion Lennox, Cordoba, CRD, Argentina

and more 51 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy